Restore Mind Medicine

Flawed Clinical Development Strategy The apparent value driver of a biotechnology company is their clinical program and bringing drugs to market. We believe that a demonstrated ability to execute is imperative. We contend that MindMed under Barrow's tenure has persistently failed: X to meet critical timelines, X develop an effective regulatory strategy with the FDA, and X advance a clinical program that drives value. MindMed's failings have led to value destruction and stem from a lack of expertise and experience. 25

View entire presentation